Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $21.146 million which beat the analyst consensus estimate of $17.914 million by 18.04 percent. This is a 4.57 percent increase over sales of $20.222 million the same period last year.